Sommaire

Numéro précédent | Numéro suivant

• • ·Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery

    Page :14S

    George Melnik, Wayne H. Schwesinger, Lisa C. Dogolo, Renli Teng, John Vincent

    Résumé Résumé Plan Plan  
• • ·Penetration of trovafloxacin into gynecologic tissues

    Page :18S

    Mark G Martens, Maurizio Maccato, Catherine Van Hook, John Vincent

    Résumé Résumé Plan Plan
• • ·The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects

    Page :23S

    John Vincent, Renli Teng, Shawn M. Pelletier, Susan A. Willavize, Hylar L. Friedman

    Résumé Résumé Plan Plan
• • ·A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers

    Page :27S

    Claartje H.M van Nispen, Andy I.M Hoepelman, Marja Rozenberg-Arska, Jan Verhoef, Lynn Purkins, Susan A Willavize

    Résumé Résumé Plan Plan  
• • ·The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects

    Page :32S

    John Vincent, Thomas Hunt, Renli Teng, Lisa Robarge, Susan A. Willavize, Hylar L. Friedman

    Résumé Résumé Plan Plan  
• • ·Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection

    Page :39S

    Andrew B Onderdonk

    Résumé Résumé Plan Plan  
• • ·Double-blind comparison of single-dose alatrofloxacin and cefotetan as prophylaxis of infection following elective colorectal surgery

    Page :46S

    Jeffrey W. Milsom, David L. Smith, Marvin L. Corman, Richard A. Howerton, Albert E. Yellin, David R. Luke, the Trovafloxacin Surgical Group†The members of the group are listed in the acknowledgments at the end of this article. †

    Résumé Résumé Plan Plan
• • ·Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin

    Page :53S

    Philip E. Donahue, David L. Smith, Albert E. Yellin, Steven J. Mintz, François Bur, David R. Luke, the Trovafloxacin Surgical Group∗A full list of group members is given in the acknowledgments. ∗

    Résumé Résumé Plan Plan  
• • ·Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease

    Page :62S

    Subir Roy, David Hemsell, Stephen Gordon, David Godwin, Mark Pearlman, David Luke, the Trovafloxacin Surgical Group∗The members of the Trovafloxacin Surgical Group are listed in the Acknowledgments. ∗

    Résumé Résumé Plan Plan
• • ·Treatment of acute gynecologic infections with trovafloxacin

    Page :67S

    Subir Roy, William Koltun, Ashwin Chatwani, Mark G. Martens, Richard Dittrich, David R. Luke, the Trovafloxacin Surgical Group∗Members of the Trovafloxacin Surgical Group are listed in the Acknowledgments. ∗

    Résumé Résumé Plan Plan  
• • ·Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin

    Page :74S

    Debra J Williams, Scott Hopkins

    Résumé Résumé Plan Plan
• • ·Antimicrobial agents for the prevention and treatment of abdominal infections: a new generation?

    Page :80S

    Ori D Rotstein

    Plan Plan
• • ·Pharmacokinetics and metabolism of single oral doses of trovafloxacin

    Page :8S

    John Vincent, Renli Teng, Deepak K. Dalvie, Hylar L. Friedman

    Résumé Résumé Plan Plan  
• • ·Antimicrobial therapy for surgical prophylaxis and for intra-abdominal and gynecologic infections

    Page :1S

    John A Weigelt, Sebastian Faro

    Plan Plan
• • ·Overview of quinolones in the treatment and prevention of surgical infection

    Page :4S

    John A Weigelt

    Résumé Résumé Plan Plan